Faculty

Karen Wernli

Affiliate Associate Professor, Epidemiology
Affiliate Associate Professor, Health Systems and Population Health

206-287-2934
Karen.j.Wernli@kp.org

Education

PhD Epidemiology, University of Washington, 2006
MS Epidemiology, University of Texas, 1998
BS Animal Physiology, University of California (San Diego), 1995

Contact

206-287-2934
Karen.j.Wernli@kp.org

1730 Minor Ave., Suite 1600
Seattle, WA 98101
View Website »

Research Areas

Research Interests

Comparative effectiveness research; cancer screening and diagnostic, preventive services, methodology

Recent Publications (PubMed)

Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network.
(2023 Jan 11)
medRxiv
Tartof SY, Xie F, Yadav R, Wernli KJ, Martin ET, Belongia EA, Gaglani M, Zimmerman RK, Talbot HK, Thornburg N, Flannery B, Chung JR, US Flu VE Network Investigators
Performance of statistical and machine learning risk prediction models for surveillance benefits and failures in breast cancer survivors.
(2023 Jan 25)
Cancer Epidemiol Biomarkers Prev
Su YR, Buist DS, Lee JM, Ichikawa L, Miglioretti DL, Aiello Bowles EJ, Wernli KJ, Kerlikowske K, Tosteson A, Lowry KP, Henderson LM, Sprague BL, Hubbard RA
Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020.
(2023 Feb)
Emerg Infect Dis 29(2): 278-285
Shafer L, Ahmed F, Kim S, Wernli KJ, Jackson ML, Nowalk MP, Bear T, Zimmerman RK, Martin ET, Monto AS, Gaglani M, Reis M, Chung JR, Flannery B, Uzicanin A
Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season.
(2022 Dec 12)
Clin Infect Dis
Price AM, Flannery B, Talbot HK, Grijalva CG, Wernli KJ, Phillips CH, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Mutnal M, Geffel KM, Nowalk MP, Tartof SY, Florea A, McLean C, Kim SS, Patel MM, Chung JR
Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
(2023 Feb 1)
J Clin Oncol 41(4): 859-870
Jayasekera J, Zhao A, Schechter C, Lowry K, Yeh JM, Schwartz MD, O'Neill S, Wernli KJ, Stout N, Mandelblatt J, Kurian AW, Isaacs C
Show complete publication list